Drug giant Merck acquires Seattle biotech Immune Design for $300 million
The deal comes four months after Immune Design Corp. halted its lead cancer vaccine trial and restructured its drug development plans.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Casey Coombs Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Merck | Vaccines